BASF ends pursuit of Evonik after two offers rejected

BASF SE (BASFn) ended its pursuit of Evonik Industries AG after two offers were rejected. BASF proposed 24 euros per share, but Evonik deemed it not in shareholders' best interests. BASF cited valuation concerns and lack of engagement from Evonik's board. The decision aligns with BASF's strategy of disciplined capital allocation.

Original reporting
Published Nov 19, 2026, 2:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 2:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$BAS.DE
Neutral
medium confidence
Mentioned
$BAS.DE · $EVKIF
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BAS.DENeutralMed
01

Why it matters

Ending the pursuit removes a near-term M&A catalyst and highlights BASF’s valuation discipline, which can shift investor focus back to organic growth and shareholder distributions.

02

Market read

Traders may adjust BASF’s deal probability assumptions and any relative-value positioning tied to European chemicals consolidation.

03

What to watch

The article does not disclose the full terms of the rejected proposals or Evonik’s counter-position, so the market may overreact without knowing whether a revised offer could still emerge.

Relevance 7/10Novelty 7/10Timing: today, deal-exit headline can drive near-term repricing

Background

BASF pursued a proposed combination with Evonik after indicating willingness to consider a moderate increase, but said it received no meaningful engagement from Evonik’s Executive Board.

Company-level read

Ticker impact

$BAS.DENeutralMedium confidence
Context

BASF ended its Evonik takeover effort after Evonik rejected two non-binding, all-cash offers, citing valuation limits and risk concerns.

Expected impact

Shares may face mild downside or volatility as the market re-prices the abandoned combination and any deal-related synergy hopes.

Evidence & confidence

The article is a first-order corporate development that removes a potential catalyst, but it does not provide deal economics beyond the stated 24 euros per share and lacks Evonik’s response.

Market effects

Signals disciplined M&A posture in specialty chemicals, potentially lowering deal-premium expectations across European chemical peers.

European industrials and chemicals sentiment may soften on reduced consolidation odds.

Limited direct global spillover, but it can affect cross-border chemical M&A sentiment.

Counterpoint

BASF’s withdrawal could be interpreted as a valuation reset that preserves optionality for a later, better-structured bid if Evonik’s standalone outlook deteriorates.

Key entities

  • BASF SE

    Specialty chemicals company that withdrew from acquiring Evonik after two rejected non-binding all-cash offers.

  • Evonik Industries AG

    Specialty chemicals company that rejected BASF’s non-binding all-cash offers and did not provide disclosed response in the article.

Related articles

$BAS.DEMed

Evonik shares rise on report BASF prepares renewed takeover offer

BASF (BASFn) is reportedly preparing a renewed takeover offer for Evonik (EVKn) after an earlier €11 billion bid was rejected. BASF is seeking input from German lawmakers and stakeholders to address regulatory and political concerns. Evonik's shares rose 3.3%, while BASF's fell 2.2% on the news. According to Bloomberg, BASF is offering structural guarantees to secure support for the deal.